ArticleJournal of lipid and atherosclerosis2026
Combination of Fimasartan and Statins in Patients With Hypertension and Dyslipidemia.
Article in Journal of lipid and atherosclerosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to investigate the efficacy and safety of a combination of fimasartan 30 mg and moderate-intensity statins in patients with hypertension and dyslipidemia in a real-world setting. Methods: This non-interventional, multicenter, prospective observational study included 5,264 patients receiving a combination of fimasartan 30 mg and moderate-intensity statins with 12-week follow-up data. Co-primary efficacy outcomes were the percentage of patients that achieved target blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) control. Safety outcomes included adverse drug reactions and treatment-emergent adverse events. Results: At 12 weeks, the proportion of patients individually achieving target BP and LDL-C was 74.4% (95% confidence interval [CI], 73.2-75.5) and 85.6% (95% CI, 84.5-86.8), respectively. The proportion of patients achieving simultaneous control of target BP and LDL-C was 65.6% (95% CI, 64.1-67.2). The median (interquartile range; IQR) differences in systolic and diastolic BPs from baseline to 12 weeks were -8.0 mmHg (-19.0 to 0.0) and -4.0 mmHg (-11.0 to 0.0), respectively (both Conclusion: Findings of this study demonstrate that a combination of fimasartan 30 mg and moderate-intensity statins results in excellent control of BP and LDL-C levels without any safety issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.